siRNA for inhibiting the expression of NK cell KIR 2DL1 receptor and its application

By designing siRNA that inhibits KIR 2DL1 receptor in NK cells and using recombinant adenovirus technology, the immune side effects in the antibody blocking strategy were solved, significantly enhancing the killing activity of NK cells, and effectively preventing and treating viruses and tumors.

CN111778245BActive Publication Date: 2024-12-03HUACHUANG WANTAI TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202010413246.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-05-15
Publication Date
2024-12-03
Estimated Expiration
2040-05-15

AI Technical Summary

Technical Problem

When the prior art uses antibodies to block the KIR receptor, it is easy to trigger immune side effects and abnormal immune responses, and it is difficult to effectively regulate the killing activity of NK cells, especially in terms of antiviral and anti-tumor effects.

Method used

By designing and using siRNA sequences to inhibit KIR 2DL1 receptor expression in NK cells, siRNA was transfected into target cells using recombinant adenovirus, significantly reducing the expression of KIR 2DL1 receptor, thereby activating NK cells and enhancing their killing activity.

Benefits of technology

The specific activation and killing activity of NK cells has been significantly enhanced, and it is effectively used for antiviral and anti-tumor prevention and treatment, avoiding the immune side effects in antibody technology.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN111778245B_ABST
    Figure CN111778245B_ABST
Patent Text Reader

Abstract

The embodiment of the present invention discloses a siRNA for inhibiting the expression of NK cell KIR 2DL1 receptor and its application, belonging to the field of biotechnology. The siRNA sequence is 2DL1-1 or / and 2DL1-2, wherein the sense strand of 2DL1-1 is shown in SEQ ID NO.1, and the antisense strand is shown in SEQ ID NO.2; the sense strand of 2DL1-2 is shown in SEQ ID NO.3, and the antisense strand is shown in SEQ ID NO.4. The siRNA of the present invention can obviously and specifically inhibit the expression of KIR 2DL1 receptor, can activate NK cells, and significantly enhance the killing activity, and can be effectively applied to the prevention and treatment of antiviral and anti-tumor.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The embodiments of the present invention relate to the field of biotechnology, and specifically to a siRNA technology for inhibiting the expression of NK cell KIR 2DL1 receptor and its application. Background Art

[0002] Stem cells and immune cells are the hottest frontier technologies in modern medicine. It can be said that without the participation of these two cells, it will be difficult to make leaps and bounds in the treatment of major diseases, common diseases, chronic diseases, aging and degenerative diseases in modern medicine. Among them, immune cells are the functional subjects of human immunology and play a supporting role in the immune system. Natural killer cells (NK cells) are important members of cellular immunity and an important part of innate immunity. Because they play an important role in innate immunity, basic immunity, and immune regulation, and do not require pre-activation when they play a role, they play an important role in the function of the human immune system and are highly valued by the industry in clinical applications in the field of immunology.

[0003] In recent years, NK cells have been highly valued by the industry and have been favored in cancer prevention, tumor immunotherapy, health management and anti-aging. NK cells play an important role in innate immunity and basic immunity; and they do not need to be pre-activated when they play a role. They can eliminate and remove pathogens in time as soon as pathogens invade the human body to avoid causing diseases; they can also directly kill mutated, cancerous, and aging cells in the body without early warning, instructions, mobilization and other processes. They are an important part of the human body's frontier defense, maintaining the stability of the internal environment, and the coordinated combat of the immune system. Due to the above-mentioned functional roles and characteristics of NK cells, they can play a very convenient, broad-spectrum, and non-specific role, but the defects that arise are non-specific and relatively weak targeted effects, especially in the treatment of viral diseases and malignant diseases, which often show problems such as insufficient force and uncertain efficacy.

[0004] Killer immunoglobulin-like receptors (KIR) are members of the immunoglobulin-like superfamily and are inhibitory regulatory pathways on NK cells that can inhibit NK activation and lytic activity. KIR receptors are a family with 18 members, namely KIR 1D, KIR 2DL1-5, KIR 2DS1-5, KIR 3DL1-3, KIR3DS1, pseudogenes xv, x, and KIR 2DP1. According to the current international KIR gene naming method, the D in the KIR gene represents the Ig-like structure in its extracellular structure, 2D and 3D represent 2 or 3 Ig-like structures outside the cell, L and S represent the length of the intracellular tail segment, which is placed at the end of the name, and the numbers behind represent different members. Studies have shown that the killing function of NK cells can be improved by regulating the activity of the KIR receptor pathway.

[0005] The prior art records the KIR receptor blocking strategy, which is mainly achieved through antibody technology and has the advantages of easy operation and good blocking effect. However, the hinge between cells and antibodies makes the following defects easy to occur in the application of this strategy: (1) Repeated infusion of NK cells carrying antibodies has certain immune side effects, such as abnormal immune response or fever; (2) NK cells with hinge antibodies have lost their natural characteristics and are easily recognized as pathological cells by the human immune system when entering the body and killed, or they may also induce abnormal immune response in the body.

[0006] RNA interference (RNAi) refers to the highly conserved phenomenon of double-stranded RNA (dsRNA)-induced efficient and specific degradation of homologous mRNA in the evolutionary process. Since RNAi technology can specifically eliminate or shut down the expression of specific genes with minimal side effects, it has been widely used to explore gene functions and treat infectious diseases and malignant tumors.

[0007] At present, the patent for activating NK cells through KIR receptor RNA interference technology only involves the activation of KIR 3DL1, which is mainly used in anti-AIDS research. Studies have shown that the expression frequency of KIR 2DL1 gene in Chinese is 82.6%, covering most individuals, the expression frequency of KIR 2DL2 gene is 47.8%, and the expression frequency of KIR 2DL3 gene is 63.0%. The expression of the three genes can cover all Chinese people. By detecting the expression and expression intensity of the three KIR receptors, one of the KIR genes can be selected for interference silencing. Therefore, this research and development team studied the above three gene silencing technologies to carry out research field applications for the regulation of the three genes separately. Summary of the invention

[0008] In order to achieve the above purpose, the embodiment of the present invention provides the following technical solutions:

[0009] According to a first aspect of an embodiment of the present invention, the present invention provides a siRNA for inhibiting the expression of NK cell KIR 2DL1 receptor, wherein the siRNA sequence is 2DL1-1 or / and 2DL1-2, wherein the sense chain of 2DL1-1 is shown as SEQ ID NO.1, and the antisense chain is shown as SEQ ID NO.2; the sense chain of 2DL1-2 is shown as SEQ ID NO.3, and the antisense chain is shown as SEQ ID NO.4.

[0010] According to a second aspect of the embodiments of the present invention, the present invention provides a recombinant adenovirus comprising the above-mentioned siRNA for inhibiting the expression of NK cell KIR 2DL1 receptor.

[0011] According to a third aspect of an embodiment of the present invention, the present invention provides a method for constructing the above-mentioned recombinant adenovirus, comprising the following steps:

[0012] S1, synthesizing a single-stranded DNA containing the above siRNA sequence, and annealing to form a double-stranded fragment with sticky ends;

[0013] S2. The target gene is cloned into the pShuttle-H1 shuttle vector, and co-transfected with the pAd-Easy backbone vector into E. coli BJ5183 competent cells to allow homologous recombination to occur in BJ5183 cells, thereby constructing a recombinant adenovirus plasmid containing the target gene;

[0014] S3. The recombinant adenovirus plasmid was digested with PacI, transfected into 293 cells via liposome-mediated transfection, and the recombinant adenovirus was obtained after packaging.

[0015] According to a fourth aspect of an embodiment of the present invention, the present invention provides use of the above-mentioned recombinant adenovirus in the preparation of antiviral and anti-tumor drugs.

[0016] The embodiments of the present invention have the following advantages:

[0017] The siRNA of the present invention can obviously and specifically inhibit the expression of KIR 2DL1 receptor, can activate NK cells, significantly enhance the killing activity, and can be effectively applied to the prevention and treatment of anti-virus and anti-tumor. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to more clearly illustrate the implementation methods of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for the implementation methods or the description of the prior art. Obviously, the drawings in the following description are only exemplary, and for ordinary technicians in this field, other implementation drawings can be derived from the provided drawings without creative work.

[0019] Figure 1 Schematic diagram of the structure of the pShuttle-H1 shuttle plasmid;

[0020] Figure 2 is the PCR identification result;

[0021] Figure 3 The sequencing results of pShuttle-H1-D1-1 are compared with the target fragment;

[0022] Figure 4-1 This is the electrophoresis diagram of recombinant plasmids No. 2 to 20. Figure 4-2 This is the electrophoresis diagram of recombinant plasmids No. 1 to 4;

[0023] Figure 5 This is the result of PacI identification of the recombinant adenovirus plasmid;

[0024] Figure 6 This is the genomic DNA identification result;

[0025] Figure 7 Schematic diagram of cesium chloride gradient centrifugation;

[0026] Figure 8 The fluorescence-labeled viral plasmid containing the target siRNA fragment was transfected into NK cells;

[0027] Fig. 9 The results are as follows 24 hours after the target gene RNA interference, showing the changes in the killing effect of NK cells on target cells;

[0028] Fig.10 The results are as follows 48 hours after the target gene RNA interference, showing the changes in the killing effect of NK cells on target cells. DETAILED DESCRIPTION

[0029] The following specific embodiments of the present invention are described. Those familiar with the technology can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in the field without creative work are within the scope of protection of the present invention. Unless otherwise specified in the methods in the following embodiments, the biochemical reagents used are all commercially available reagents, and all methods are conventional methods.

[0030] Example 1

[0031] Steps for designing siRNA to inhibit the expression of NK cell KIR receptors (2DL1, 2DL2, 2DL3):

[0032] (1) The NK cell KIR2DL1, KIR2DL2, and KIR2DL3 gene sequences were retrieved from the three gene databases of NCBI, DDBJ, and BMBL on the Internet to obtain the targeted mRNA or cDNA sequences, and the siRNA sequences were designed in the downstream sequences after +50 to +100 of the cDNA transcription region.

[0033] (2) Perform a GEN-BAND BALST query on the selected siRNA sequence to ensure that the selected siRNA coding sequence is not homologous to other gene sequences.

[0034] We first designed several candidate sequences for the three NK cell receptors KIR 2DL1, 2DL2, and 2DL3, then compared and optimized them. Finally, we determined two optimal sequences for each receptor for subsequent experiments.

[0035] The siRNA that inhibits the expression of NK cell KIR 2DL1 receptor includes two sequences: 2DL1-1 and 2DL1-2:

[0036] 2DL1-1 (target site is 267 bases): the sense strand is 5'CUUCUCCAUCAGUCGGUU3' (SEQ ID NO. 1), and the antisense strand is 5'CAUGCGACUGAUGGAGUU3' (SEQ ID NO. 2).

[0037] 2DL1-2 (target site is 250 bases): the sense strand is 5'AGUCAAGUGACCCACUUU3' (SEQ ID NO. 3), and the antisense strand is 5'AGCAGUGGGUCACUUUUU3' (SEQ ID NO. 4).

[0038] The siRNAs that inhibit the expression of NK cell KIR 2DL2 receptors include two sequences: 2DL2-1 and 2DL2-2:

[0039] 2DL2-1 (target site is 202 bases): the sense strand is 5'GGGAAGUUUAAGGACUUU3' (SEQ ID NO. 5), and the antisense strand is 5'AAGUGUCCUUAAACUCUU3' (SEQ ID NO. 6).

[0040] 2DL2-2 (target site is 258 bases): the sense strand is 5'AGCCAACUUCUCCAUUUU3' (SEQ ID NO. 7), and the antisense strand is 5'ACCGAUGGAGAAGUUUUU3' (SEQ ID NO. 8).

[0041] The siRNAs that inhibit the expression of NK cell KIR 2DL3 receptors include two sequences: 2DL3-1 and 2DL3-2:

[0042] 2DL3-1 (target site is 857 bases): the sense strand is 5'UGCUGUUGUAAUGGAAUU3' (SEQ ID NO. 9), and the antisense strand is 5'UUGGUCCAUUACAACAUU3' (SEQ ID NO. 10).

[0043] 2DL3-2 (target site is 902 bases): the sense strand is 5'CAGGGAGGACUCUGAAUU3' (SEQ ID NO. 11), and the antisense strand is 5'UUCAUCAGAGUCCUCGUU3' (SEQ ID NO. 12).

[0044] Example 2

[0045] (I) Synthesis of single-stranded DNA containing siRNA sequence

[0046] A single-stranded DNA containing a siRNA sequence is synthesized by chemical synthesis, including a positive DNA strand and a reverse DNA strand, wherein the positive DNA strand corresponds to the sense strand of the siRNA sequence, and the reverse DNA strand corresponds to the antisense strand of the siRNA sequence. Specifically,

[0047] Single-stranded DNA containing siRNA sequence that inhibits the expression of NK cell KIR 2DL1 receptor:

[0048] D1-1:

[0049] The positive strand is 5'TCGACCCCTTCTCCATCAGTCGCATGTTCAAGAGACATGCG ACTTTTTTGGAAA3' (SEQ ID NO. 13),

[0050] The reverse strand is 5'GATCTTTCCAAAAACTTCTCCATCAGTCGCATGTCTCTTGA ACATGCGACTGATGGG3' (SEQ ID NO. 14).

[0051] D1-2:

[0052] The positive strand is 5'TCGACCCAGTCAAGTGACCCACTGCTTTCAAGAGAAGC AGTGGGTTTTTGGAAA3' (SEQID NO.15),

[0053] The reverse strand is 5'GATCTTTCCAAAAAAGTCAAGTGACCCACTGCTTCTCTT GAAAGCAGTGGGTCACGG3' (SEQ ID NO. 16).

[0054] Single-stranded DNA containing siRNA sequence that inhibits the expression of NK cell KIR 2DL2 receptor:

[0055] D2-1:

[0056] The positive strand is 5'TCGACCCGGGAAGTTTAAGGACACTTTTCAAGAGAAAG TGTCCTTTTTTGGAAA3' (SEQID NO.17),

[0057] The anti-strand is 5'GATCTTTCCAAAAAGGGAAGTTTAAGGACACTTTCTCTT GAAAAGTGTCCTTAAGG3' (SEQ ID NO. 18).

[0058] D2-2:

[0059] The positive strand is 5'TCGACCCAGCCAACTTCTCCATCGGTTTCAAGAGAACC GATTTTTTTGGAAA3' (SEQ ID NO. 19),

[0060] The reverse strand is 5'GATCTTTCCAAAAATGCTGTTGTAATGGACCAATCTCTTGAATTGGTCCATTACAACAG3' (SEQ ID NO. 20).

[0061] Single-stranded DNA containing siRNA sequence that inhibits the expression of NK cell KIR 2DL3 receptor:

[0062] D3-1:

[0063] The positive strand is 5'TCGACCCTGCTGTTGTAATGGACCA ATTCAAGAGATTG GTCCATATTTTTGGAAA3' (SEQ ID NO.21),

[0064] The reverse strand is 5'GATCTTTCCAAAAATGCTGTTGTAATGGACCAATCTCTTG AATTGGTCCATTACAAGG 3' (SEQ ID NO. 22).

[0065] D3-2:

[0066] The positive strand is 5'TCGACCCCAGGGAGGACTCTGATGAATTCAAGAGATTC ATCAGATTTTTGGAAA3' (SEQID NO.23),

[0067] The reverse strand is 5'GATCTTTCCAAAAACAGGGAGGACTCTGATGAATCTCTT GAATTCATCAGAGTCCTCG3' (SEQ ID NO. 24).

[0068] At the same time, unrelated controls that do not target any NK cell KIR genes were designed:

[0069] The positive strand is 5'TCGACCCTCTCGTATGTAGTGGCCTGTTCAAGAGACAGG CCACTATTTTTGGAAA3' (SEQ ID NO. 25),

[0070] The reverse strand is 5'GATCTTTCCAAAAATCTCGTATGTAGTGGCCTGTCTCTTG AACAGGCCACTAGG 3' (SEQ ID NO. 26).

[0071] The corresponding DNA positive strands and reverse strands are annealed to form double-stranded fragments D1-1, D1-2, D2-1, D2-2, D3-1, D3-3 and irrelevant controls with sticky ends.

[0072] (II) Construction and identification of recombinant shuttle plasmid

[0073] 1. Double digestion of pShuttle-H1 with SalI and BglII

[0074] Enzyme digestion system: 10×H Buffer: 5.0 μl, SalI: 1.0 μl, BglII: 1.0 μl, pShuttle-H1: 25.0 μl, sterile water: 18.0 μl, reaction conditions: incubate at 37°C for 2 h.

[0075] 2. Recovery of enzyme digestion products

[0076] The digested product was subjected to 0.8% agarose gel electrophoresis for a sufficient period of time, and then the target fragment was recovered using the TIANGEN agarose gel recovery kit:

[0077] (1) The digested product was subjected to 0.8% agarose gel electrophoresis, and the target band was cut out and placed in a 1.5 ml EP tube;

[0078] (2) Add 300 μl PN / 100 μg gel and incubate in a 50-60°C water bath for 10 min, mixing constantly to allow the mixture to fully dissolve.

[0079] (3) Transfer it to the CB3 column in the collection tube and let it stand for 1 min;

[0080] (4) Centrifuge at 12000 rpm for 1 min and discard the liquid in the collection tube;

[0081] (5) Add 700 μl of washing solution PW, centrifuge at 12000 rpm × 1 min, and discard the liquid in the collection tube;

[0082] (6) Add 500 μl of washing solution PW, centrifuge at 12000 rpm × 1 min, and discard the liquid in the collection tube;

[0083] (7) Centrifuge at 12000 rpm for 2 min, place the CB3 column in a sterilized 1.5 ml EP tube, and add 30 μl of sterile water to the CB3 column (add to the center of the membrane);

[0084] (8) After standing at room temperature for 5 min, centrifuge at 10700 rpm for 1 min and store the obtained product at -20°C for later use.

[0085] 3. Unrelated control, D1-1, D1-2, D2-1, D2-2, D3-1, D3-2 and the recovered enzyme digestion products were connected

[0086] Ligation system: 10×Ligase Buffer: 1.0μl, Ligase: 0.5μl, irrelevant control / D1-1 / D1-2 / D2-1 / D2-2 / D3-1 / D3-2: 0.5μl, recovery of enzyme cleavage product: 4.0μl, sterile water: 4.0μl, reaction conditions: in a 24℃ water bath for 1h.

[0087] 4. Transform DH5a competent cells with ligation products

[0088] (1) Mix 5 μl of ligation product with 100 μl of competent cells and place on ice for 30 min;

[0089] (2) After removal, heat shock in a 42°C water bath for 90 seconds;

[0090] (3) Place on ice for 3 to 5 minutes;

[0091] (4) Add 600 μl of LB medium and shake at 37°C at 200 rpm for 40 min;

[0092] (5) Take out 400 μl and spread it on a Kana+LB plate and culture it in an incubator at 37°C overnight.

[0093] 5. Clone picking, plasmid extraction and purification

[0094] (1) Pick a single colony and inoculate it into 5 ml of Kana+LB liquid medium, and shake it in a shaker at 37°C at 250 rpm overnight;

[0095] (2) Extract the plasmid from each tube (TIANGEN)

[0096] (2-1) Collect the culture medium in a 5 ml centrifuge tube and centrifuge at 8000 rpm for 10 min to collect the bacterial liquid;

[0097] (2-2) Resuspend the cells in 250 μl of solution P1 and transfer them to a 1.5 ml EP tube;

[0098] (2-3) Add 250 μl of lysis buffer P2 and gently invert the EP tube 6 to 8 times;

[0099] (2-4) Add 350 μl of neutralizing solution P3, gently invert the EP tube 6 to 8 times, and then centrifuge at 12,000 rpm for 10 min;

[0100] (2-5) Transfer the supernatant to a CB1 column (placed in a collection tube) and centrifuge at 12000 rpm × 1 min;

[0101] (2-6) Discard the liquid in the collection tube, add 700 μl of washing solution PW to the CB1 column, and centrifuge at 12000 rpm × 1 min;

[0102] (2-7) Discard the liquid in the collection tube, add 500 μl of washing solution PW to the CB1 column, and centrifuge at 12000 rpm × 1 min;

[0103] (2-8) Discard the liquid in the collection tube and centrifuge at 12000 rpm for 2 min;

[0104] (2-9) Place the CB1 column in a sterile EP tube, add 50 μl of sterile water to the center of the column, and leave at room temperature for 5 min;

[0105] (2-10) Centrifuge at 10700 rpm × 1 min to collect the product;

[0106] (3) The extracted plasmids were subjected to electrophoresis, and all plasmid bands appeared, which were preliminarily identified as positive clones.

[0107] 6. PCR identification of plasmid

[0108] PCR primers P1 and P2 were designed to be located on both sides of the inserted fragment, and then PCR amplification was performed using pShuttle-H1 as a control.

[0109] P1: 5'CTgggAAATCACCATAAACg3'

[0110] P2: 5'CTgCAAAACAgATACAAAACTACA3'

[0111] PCR reaction system:

[0112] Extracted plasmid: 0.5μl, primer P1: 0.5μl, primer P2: 0.5μl, 2×PCR mix: 10μl, sterile water: 8.5μl. Temperature cycle program: 95℃ heating for 2min; 95℃ heating for 30s, 60℃ heating for 30s; 72℃ heating for 30s; 95℃ to 72℃ for 29 cycles; 72℃ heating for 10min; 22℃ heating for 1min;

[0113] The amplified products were subjected to 1.0% agarose gel electrophoresis. Figure 2 , where 1 to 6 are the PCR amplification products of clones 1 to 6, N is an irrelevant control of the pShuttle-H1 amplification product, and D is the DL2000 Marker. The results show that clones 1, 2, 3, 4, 5, and 6 were correctly identified.

[0114] 7. The clones that were identified correctly were sent to Beijing Aoke Biotechnology Co., Ltd. for sequencing. The sequencing results were consistent with the target fragment (taking pShuttle-H1-D1-1 as an example, the results were as follows Figure 3 The results showed that we successfully obtained the recombinant shuttle plasmids: pShuttle-H1-control (irrelevant control), pShuttle-H1-D1-1, pShuttle-H1-D1-2, pShuttle-H1-D2-1, pShuttle-H1-D2-2, pShuttle-H1-D3-1, and pShuttle-H1-D3-2.

[0115] (III) Construction and identification of recombinant adenovirus plasmids

[0116] 1. PmeI digests the recombinant shuttle plasmid and performs dephosphorylation treatment

[0117] Enzyme digestion system: recombinant shuttle plasmid (pShuttle-H1-control (irrelevant control), pShuttle-H1-D1-1, pShuttle-H1-D1-2, pShuttle-H1-D2-1, pShuttle-H1-D2-2, pShuttle-H1-D3-1, pShuttle-H1-D3-2): 30 μl, Buffer 4: 5 μl, BSA: 5 μl, PmeI: 2 μl, sterile water: 8 μl, reaction conditions: incubated at 37 °C for 4 h;

[0118] 2. Perform 1.0% agarose gel electrophoresis on the digested product and recover the product by cutting the gel (the operation method is the same as before);

[0119] 3. Dephosphorylation of rubber tapping products

[0120] Reaction system: recovered product: 20 μl, dephosphorylase: 1.0 μl, phosphorylase buffer: 3.0 μl, sterile water: 6.0 μl, reaction conditions: incubate at 37°C for 1 h; inactivation treatment: incubate at 65°C for 5 min;

[0121] 4. Take 5 μl of the dephosphorylated enzyme digestion product and electro-transform BJ5183 competent cells containing pAdeasy-1 for homologous recombination;

[0122] 5. After selecting clones and extracting plasmids, perform 0.6% agarose gel electrophoresis and use the recombinant shuttle plasmid as a control to observe the plasmid recombination. The results are as follows: Figure 4-1 As shown, 1 is the pShuttle-H1-D1-1 plasmid, 2 to 5 are clones 1 to 4 of the pShuttle-H1-D1-1 recombinant adenovirus plasmid, 6 to 9 are clones 1 to 4 of the pShuttle-H1-D1-2 recombinant adenovirus plasmid, 10 to 13 are clones 1 to 4 of the pShuttle-H1-D2-1 recombinant adenovirus plasmid; 14 to 17 are clones 1 to 4 of the pShuttle-H1-D3-1 recombinant adenovirus plasmid, 18 to 20 are clones 1 to 3 of the pShuttle-H1-control recombinant adenovirus plasmid; H is DL2000 Marker. Figure 4-2 In the figure, 1 is the pShuttle-H1-D2-2 recombinant adenovirus plasmid clone, 3 is the pShuttle-H1-D3-2 recombinant adenovirus plasmid clone, 2 and 4 are other clones used as references, and 5 is DL2000Marker. Preliminary results show that Figure 4-1 2, 3, 4, 5, 7, 8, 9, 10, 12, 13, 14, 16, 18, 19 and Figure 4-21 and 3 are clones with successful recombination, and it was preliminarily determined that Ad-pShuttle-H1-D1-1, Ad-pShuttle-H1-D1-2, Ad-pShuttle-H1-D2-1, Ad-pShuttle-H1-D2-2, Ad-pShuttle-H1-D3-1, Ad-pShuttle-H1-D3-2, and Ad-pShuttle-H1-control were obtained.

[0123] 6. Select some recombinant adenovirus plasmids that have been initially identified as correct and perform PacI digestion identification. The results are as follows: Figure 5 As shown, 1 is the No. 1 clone of the pShuttle-H1-D1-1 recombinant adenovirus plasmid, 2 is the No. 2 clone of pShuttle-H1-D1-2, 3 is the No. 1 clone of the pShuttle-H1-D2-1 recombinant adenovirus plasmid, 4 is the No. 1 clone of the pShuttle-H1-D3-1 recombinant adenovirus plasmid, 5 is the No. 1 clone of the pShuttle-H1-control recombinant adenovirus plasmid, and H is λ-HindIIIMarker. It shows that the selected clones are all target clones and can be used for the next experiment;

[0124] 7. Re-use one-to-one primers to amplify the PCR amplification results of the corresponding sequences of the recombinant adenovirus Ad-pshuttle-H1-D1-1, Ad-pshuttle-H1-D1-2, Ad-pshuttle-H1-D2-1, Ad-pshuttle-H1-D3-1, and Ad-pshuttle-H1-control. C is the normal 293 cell genomic DNA, and D is the DL2000 Marker. The results are shown in Figure 6 The results showed that the KIR siRNA sequences contained in the above five adenoviruses were successfully amplified one by one, indicating that the inserted sequence was correct.

[0125] (IV) Construction and identification of recombinant adenovirus

[0126] 1. Adenovirus packaging: Culture the 293 cells packaged with the virus in a 6 cm culture dish in DMEM medium until the cells reach 50%-70% confluence, add 2 μg of recombinant adenovirus plasmid for transfection, and replace with fresh medium after 6 hours;

[0127] 2. Virus collection: Observe whether virus plaques are formed before virus collection. In order to limit the spread of the virus and allow plaques to form better, low melting point agarose is usually added to the culture medium. Generally, plaques are formed 10-21 days after virus transfection. After the plaques are formed, pick up the plaques together with the agarose and place them in 1 ml of fresh culture medium overnight. Usually 3-6 plaques are picked, and then the titers are compared. The plaque with the highest titer is used for subsequent experiments;

[0128] 3. Virus amplification: On the second day, add the virus in the culture medium to fresh 293 cell culture medium for a small amount of virus amplification. When the cells show plaques again, collect the cells and supernatant, freeze and thaw repeatedly three times to collect the virus, and use this virus as the P1 generation virus. Infect 293 cells with the P1 generation adenovirus, and continue to infect for three generations. Amplify the adenovirus in large quantities to the P4 generation. After the plaques are formed, collect the virus and purify and concentrate the virus in vitro;

[0129] 4. Virus purification: Virus purification uses PEG8000 precipitation-CsCI density gradient centrifugation-dialysis combined method to purify the virus. The specific operation is as follows:

[0130] (1) Thawing: Take the virus out of the -80°C freezer one day in advance and thaw it in a water bath at room temperature. Collect all cell lysates, centrifuge at 7000 × g for 10 min at 4°C, discard cell debris, and collect the supernatant.

[0131] (2) PEG8000 precipitation: add 50 ml PEG8000 (20% PEG8000, 2.5 M NaCI) to every 100 ml supernatant, place on ice for 1 hour to precipitate the virus (the time can be extended appropriately). Centrifuge the above mixture at 7000×g for 20 minutes at 4°C, discard the supernatant, and suspend the precipitate in 10 ml CsCI solution with a density of 1.10 g / ml (solvent is 20 Mm Tris-HCl, pH 8.0). The virus solution is red. The results of virus density centrifugation of 1 to 6 are shown in the figure. Figure 7 ;

[0132] (3) CsCI gradient centrifugation: The CsCI gradient was prepared by adding 2 ml of a CsCI solution with a density of 1.40 g / ml (solvent as above), then slowly adding 3 ml of a CsCI solution with a density of 1.30 g / ml, and then adding 5 ml of the virus suspension, and centrifuging at 26,000 rpm at 4°C for 2 h using a Beckman SW28 rotor;

[0133] (4) Virus collection: Use a syringe to collect the virus band with a density between 1.30 g / ml and 1.40 g / ml into a dialysis bag;

[0134] (5) Dialysis: In dialysis buffer (50 g sucrose, 10 ml 1M Tris-HCl, pH 8.0, 2 ml 1M MgCl2 to 1 L), stir overnight at 4°C. The dialysis solution needs to be replaced once in the middle, and the virus is collected and the virus titer is determined;

[0135] (6) Resuspend: Resuspend the virus pellet in 500 μl. If used within one week, store at 4°C. If required for long-term storage, store at -80°C.

[0136] 5. Determination of adenovirus titer

[0137] Plaques are dots formed by virus-induced cell lysis and can be observed under a microscope and with the naked eye. Plaque forming units (PFU) are the number of plaques formed per unit volume of virus and are units representing the concentration of active virus particles.

[0138] PFU determination method: 293 cells were plated in a 60 mm culture dish. After 24 hours, when the cell density was close to 100%, different dilutions of virus were added, and the cells were infected at 37°C for 4-8 hours. 8 ml of low melting point gel (10% FBS, 1.25% Agarose) was plated. After 9-11 days of culture, the plaques were counted to calculate the virus titer.

[0139] 6. Observation of virus transfection efficiency

[0140] In vitro experimental study, transfected target cells, using EGFP fluorescent marker to observe transfection efficiency, the results are shown in Figure 8 ,in, Figure 8-1 , 8-2, 8-3, 8-4, 8-5, and 8-6 were respectively used to observe the efficiency of 6 viruses in transfecting target cells. The results showed that the transformation system was stable and effective, and more than 90% of the efficient transformation was achieved in one transfection.

[0141] Example 3

[0142] (I) K562 cell culture

[0143] K562 cells were cultured in RPMI-1640 medium. During the cell culture process, 5%-20% fetal bovine serum was often added. The initial inoculation of cells was 1×10 6 cells / bottle.

[0144] 1. When the cells cover the entire plate (100 mm), discard the old culture medium and wash once with 10 ml PBS;

[0145] 2. Digest with 2 ml of 0.25% trypsin (preheated for about 20 minutes), shake gently until the monolayer cells fall off in blocks (or observe the separation of cells under a microscope), immediately add 5 ml (RPMI-1640 + 10% FBS) to terminate digestion, and gently pipette 8-10 times to separate into single cells;

[0146] 3. Centrifuge at 1000rpm*5min, discard the supernatant, add RPMI-1640+10% FBS and pipette gently;

[0147] 4. Transfer the cell suspension at a ratio of 1:4 to a 100 mm cell culture dish. Add 10 ml (RPMI-1640 + 10% FBS) culture medium to each dish. Normally, the dish will be fully grown in 2-3 days without changing the medium.

[0148] (II) Experiment on siRNA inhibition of NK cell KIR 2DL1 receptor expression

[0149] 1. Peripheral blood collection: 30 ml, heparin anticoagulation

[0150] 2. Culture flask plating

[0151] (1) Place the co-activator (30 ml) in a 37°C water bath to warm for 10 min and mix gently;

[0152] (2) Place the activator (2 ml) in a 37°C water bath to warm for 10 min and mix gently;

[0153] (3)225cm 2 Add 2 ml of activator and 30 ml of co-activator to the culture bottle and mix well. Seal the culture bottle and place it in a 4°C refrigerator overnight. It can be used and stored for 2 weeks (it is recommended to be longer than 24 hours).

[0154] 3. Cytokine preparation

[0155] Before cell culture, take out IL-2 (1 million units / vial) and IL-15 (100 μg / vial), add 1 ml and 2 ml of NK cell dominant expansion medium respectively, mix gently, place in a 4°C refrigerator, and use within 2 weeks;

[0156] 4. Mononuclear cell isolation, plasma collection and processing

[0157] (1) Open the water bath and adjust the temperature to 56°C to prepare for fire extinguishing and replenishment;

[0158] (2) Routine aseptic collection of 30 ml of peripheral blood, anticoagulated with heparin;

[0159] (3) Before isolating mononuclear cells, place the pre-plated culture flask in a 37°C incubator;

[0160] (4) Dilute the peripheral blood 1-fold with NK expansion medium, slowly add the above liquid to Ficoll-Hypaque liquid, and centrifuge by density gradient centrifugation (800g, 25-30min);

[0161] (5) Gently remove the centrifuge tube, aspirate the diluted plasma on the upper layer, inactivate complement at 56°C for 30 minutes, and then centrifuge (3000 g, 10 minutes) to remove platelets;

[0162] (6) Collect the mononuclear cell layer, mix thoroughly with saline, and wash by centrifugation (500 g, 15 min);

[0163] Note: Adding 0.38% sodium citrate to the saline solution used for washing can reduce the contamination of platelets.

[0164] (7) Resuspend the cell pellet in saline and wash it again by centrifugation (500 g, 8-10 min);

[0165] (8) Use NK cell expansion medium to suspend cells. Take 10 μl of cell suspension, add 90 μl of white blood cell diluent (or 3% glacial acetic acid), mix well and count the cells;

[0166] 5. Cell culture

[0167] (1) Take out the culture flask that has been pre-plated and incubated at 37°C, aspirate the diluted activator, and do not wash;

[0168] (2) According to the cell counting results, the final cell concentration was adjusted to 1.5-2×10 6 / ml. IL-2, IL-15 and autologous plasma were added to the mononuclear cell suspension. IL-2 and IL-15 were added at a ratio of 1:1000 (IL-2 or IL-15: volume of rehydration medium) (the following IL-2 and IL-15 additions were all 1:1000); the autologous plasma concentration was 2.5-5%;

[0169] (3) Add the cell suspension to the pre-plated culture flask and place it in a cell culture incubator at 37°C, 5% CO2, and saturated humidity for static culture. The next day, observe whether there is contamination; if not, continue to culture for 96 hours;

[0170] (4) Continue culturing and replenish the culture medium every three days. Replenish fresh culture medium with a total volume of 50-100 ml / bottle containing 2.5% plasma, IL-2, and IL-15;

[0171] (5) On the 14th day of culture, 100 μl of recombinant adenovirus was added to each bottle to obtain siRNA interference target gene NK cells;

[0172] (III) NK cell killing activity detection

[0173] The target cells were K562 tumor cells, and the effector cells were siRNA interference target gene NK cells, with an effector-target ratio of 20:1. Effector and target cell co-incubation wells (E+T), effector cell control wells (E) and target cell control wells (T) were set up, with 3 replicates in each group. Cells were collected at 24 and 48 hours of culture, and the CFSE / PI staining of K562 cells was detected using a flow cytometer from Becton-Dickinson, USA. The results are shown in Fig. 9 and Fig.10 , where a represents non-interfering NK control, b represents D1-1 interfering RNA, and c represents D1-2 interfering RNA.

[0174] The results showed that the killing effect was significantly increased 24 hours after transfection, which was 37.7% (2DL1-1) and 11.9% (2DL1-2) higher than that of unactivated NK; it reached a peak at 48 hours, which was 37.3% (2DL1-1) and 51.0% (2DL1-2) higher than that of unactivated NK.

[0175] Although the present invention has been described in detail above by general description and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made on the basis of the present invention. Therefore, these modifications or improvements made on the basis of not departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.

[0176]

[0177]

[0178]

[0179]

[0180]

[0181]

[0182] Sequence Listing <110> Qinhuangdao Cybergen Biotechnology Co., Ltd. <120> siRNA for inhibiting the expression of NK cell KIR 2DL1 receptor and its application <130> 202003 <160> 26 <170> SIPOSequenceListing 1.0 <210> 1 <211> 18 <212> RNA <213> Artificial Sequence <400> 1 cuucuccauc agucgguu 18 <210> 2 <211> 18 <212> RNA <213> Artificial Sequence <400> 2 caugcgacug auggaguu 18 <210> 3 <211> 18 <212> RNA <213> Artificial Sequence <400> 3 agucaaguga cccacuuu 18 <210> 4 <211> 18 <212> RNA <213> Artificial Sequence <400> 4 agcagugggu cacuuuuu 18 <210> 5 <211> 18 <212> RNA <213> Artificial Sequence <400> 5 gggaaguuua aggacuuu 18 <210> 6 <211> 18 <212> RNA <213> Artificial Sequence <400> 6 aaguguccuu aaacucuu 18 <210> 7 <211> 18 <212> RNA <213> Artificial Sequence <400> 7 agccaacuuc uccauuuu 18 <210> 8 <211> 18 <212> RNA <213> Artificial Sequence <400> 8 accgauggag aaguuuuu 18 <210> 9 <211> 18 <212> RNA <213> Artificial Sequence <400> 9 ugcuguugua auggaauu 18 <210> 10 <211> 18 <212> RNA <213> Artificial Sequence <400> 10 uugguccauu acaacauu 18 <210> 11 <211> 18 <212> RNA <213> Artificial Sequence <400> 11 cagggaggac ucugaauu 18 <210> 12 <211> 18 <212> RNA <213> Artificial Sequence <400> 12 uucaucagag uccucguu 18 <210> 13 <211> 54 <212> DNA <213> Artificial Sequence <400> 13 tcgacccctt ctccatcagt cgcatgttca agagacatgc gactttttg gaaa 54 <210> 14 <211> 57 <212> DNA <213> Artificial Sequence <400> 14 gatctttcca aaaacttctc catcagtcgc atgtctctg aacatgcgac tgatggg 57 <210> 15 <211> 54 <212> DNA <213> Artificial Sequence <400> 15 tcgacccagt caagtgaccc actgctttca agagaagcag tggttttg gaaa 54 <210> 16 <211> 57 <212> DNA <213> Artificial Sequence <400> 16 gatctttcca aaaaagtca gtgacccact gctctcttg aaagcagtgg gtcacgg 57 <210> 17 <211> 54 <212> DNA <213> Artificial Sequence <400> 17 tcgacccgggg aagtttagg acactttca agagaaagtg tcctttttg gaaa 54 <210> 18 <211> 56 <212> DNA <213> Artificial Sequence <400> 18 gatctttcca aaaagggaag tttaaggaca ctttctcttg aaaagtgtcc ttaagg 56 <210> 19 <211> 52 <212> DNA <213> Artificial Sequence <400> 19 tcgacccagc caacttctcc atcggtttca agagaaccga tttttttgga aa 52 <210> 20 <211> 59 <212> DNA <213> Artificial Sequence <400> 20 gatctttcca aaaatgctgt tgtaatggac caatctcttg aattggtcca ttacaacag 59 <210> 21 <211> 55 <212> DNA <213> Artificial Sequence <400> 21 tcgaccctgc tgttgtaatg gaccaattca agagattggt ccatattttt ggaaa 55 <210> 22 <211> 58 <212> DNA <213> Artificial Sequence <400> 22 gatctttcca aaaatgctgt tgtaatggac caatctcttg aattggtcca ttacaagg 58 <210> 23 <211> 54 <212> DNA <213> Artificial Sequence <400> 23 tcgaccccag ggaggactct gatgaattca agagattcat cagatttttg gaaa 54 <210> 24 <211> 58 <212> DNA <213> Artificial Sequence <400> 24 gatctttcca aaaacaggga ggactctgat gaatctcttg aattcatcag agtcctcg 58 <210> 25 <211> 55 <212> DNA <213> Artificial Sequence <400> 25 tcgaccctct cgtatgtagt ggcctgttca agagacaggc cactattttt ggaaa 55 <210> 26 <211> 54 <212> DNA <213> Artificial Sequence <400> 26 gatctttcca aaaatctcgt atgtagtggc ctgtctcttg aacaggccac tagg 54

Claims

1. A recombinant adenovirus, characterized in that: It includes a siRNA for inhibiting the expression of NK cell KIR 2DL1 receptor, wherein the siRNA sequence is 2DL1-1 or / and 2DL1-2, wherein the sense strand of 2DL1-1 is shown as SEQ ID NO.1, and the antisense strand is shown as SEQ ID NO.2; the sense strand of 2DL1-2 is shown as SEQ ID NO.3, and the antisense strand is shown as SEQ ID NO.

4.

2. A method for constructing a recombinant adenovirus according to claim 1, characterized in that: The following steps are involved: S1, synthesizing a single-stranded DNA containing the siRNA coding sequence of claim 1, and annealing to form a double-stranded fragment with sticky ends; S2, clone the double-stranded fragment into the pShuttle-H1 shuttle vector, co-transfect the competent cells of E. coli BJ5183 with the pAd-Easy backbone vector, and perform homologous recombination in BJ5183 to construct a recombinant adenovirus plasmid containing the target gene; S3, the recombinant adenovirus plasmid was Pac After identification by restriction enzyme digestion with I, the recombinant adenovirus was obtained by transfection into 293 cells mediated by liposomes and packaging.